Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

US10035813B2 · kind B2 · utility

Assignee

• Debiopharm International S.A.

Inventors

• John J. Partridge · Upper Montclair, US
• John Colucci · Kirkland, CA
• Yves Gareau · Notre-Dame-de-l'Île-Perrot, CA
• Michel Therien · Laval, CA
• Robert Zamboni · Rue du Bois des Loges, CA
• Barry Hafkin · Austin, US
• Anthony Marfat · Mystic, US
• Helmi Zaghdane · Pincourt, CA

Key dates

• Filing date: Nov 6, 2014
• Grant date: Jul 31, 2018
• Expiry date: Nov 6, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/662
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.